Use of known agonists of the central cannabinoid receptor CB1
Mittendorf, Joachim; Dressel, Jurgen; Matzke, Michael; Franz, Jurgen; Spreyer, Peter; Vohringer, Verena; Schuhmacher, Joachim; Friedl, Arno; Horvath, Ervin; Mauler, Frank; De Vry, Jean Marie Viktor; Jork, Reinhard
Official Gazette of the United States Patent and Trademark Office Patents 1250(1)
2001
ISSN/ISBN: 0098-1133
Accession: 036016486
The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
PDF emailed within 1 workday: $29.90
Related References
Landsman, R.S.; Waite, S.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. 1998: The effects of cannabinoid agonists and inverse agonists at the human cannabinoid CB1 receptor stably expressed in CHO cells Society for Neuroscience Abstracts 24(1-2): 1245Felder, C.C.; Veluz, J.S.; Williams, H.L.; Briley, E.M.; Matsuda, L.A. 1992: Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones Molecular Pharmacology 42(5): 838-845
Godlewski, G.; Kwolek, G.; Malinowska, B.; Barann, M.; Molderings, G.J.; Urban, B.W.; Goethert, M. 2002: Cannabinoid receptor-independent inhibition by cannabinoid receptor agonists of the 5-HT3 receptor-mediated Bezold-Jarisch reflex Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R28
Rivers, J.R.-J.; Ashton, J.C. 2010: The development of cannabinoid CBIi receptor agonists for the treatment of central neuropathies Central Nervous System Agents in Medicinal Chemistry 10(1): 47-64
Deventer, M.H.; Van Uytfanghe, K.; Vinckier, I.M.J.; Reniero, F.; Guillou, C.; Stove, C.P. 2022: Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists Drug Testing and Analysis 14(9): 1565-1575
Godlewski, G.; Göthert, M.; Malinowska, B. 2003: Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex British Journal of Pharmacology 138(5): 767-774
Kukushkin, M.L.; Igon'kina, S.I.; Churyukanov, M.V.; Churyukanov, V.V.; Bobrov, M.Y.; Bezuglov, V.V.; Gretskaya, N.V. 2006: Role of cannabinoid receptor agonists in mechanisms of suppression of central pain syndrome Bulletin of Experimental Biology and Medicine 142(1): 39-42
Shah, S.A.; Gupta, A.S.; Kumar, P. 2021: Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management Journal of Cancer Research and Therapeutics 17(1): 1-9
Maguire, D.R.; France, C.P. 2018: Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio European Journal of Pharmacology 819: 217-224
Maguire, D.R.; France, C.P. 2016: Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl European Journal of Pharmacology 784: 199-206
Moreira, F.íc.A.; Grieb, M.; Lutz, B. 2009: Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression Best Practice and Research. Clinical Endocrinology and Metabolism 23(1): 133-144
Pryce, G.; Visintin, C.; Ramagopalan, S.V.; Al-Izki, S.; De Faveri, L.E.; Nuamah, R.A.; Mein, C.A.; Montpetit, A.; Hardcastle, A.J.; Kooij, G.; de Vries, H.E.; Amor, S.; Thomas, S.A.; Ledent, C.; Marsicano, G.; Lutz, B.; Thompson, A.J.; Selwood, D.L.; Giovannoni, G.; Baker, D. 2014: Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 28(1): 117-130
Wouters, E.; Walraed, J.; Banister, S.D.; Stove, C.P. 2019: Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists Biochemical Pharmacology 169: 113623
Patel, M.; Finlay, D.B.; Glass, M. 2021: Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists Cellular Signalling 78: 109865
Slipetz, D.M.; O'neill, G.P.; Favreau, L.; Dufresne, C.; Gallant, M.; Gareau, Y.; Labelle, M.; Gresser, M.J.; Metters, K.M. 1994: The human peripheral cannabinoid receptor inhibits adenylate cyclase through interaction with cannabinoid agonists Molecular Biology of the Cell 5(Suppl ): 11A
Plowright, A.T.; Nilsson, K.; Antonsson, M.; Amin, K.; Broddefalk, J.; Jensen, Jörgen.; Lehmann, A.; Jin, S.; St-Onge, S.; Tomaszewski, Mław.J.; Tremblay, M.; Walpole, C.; Wei, Z.; Yang, H.; Ulander, J. 2013: Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease Journal of Medicinal Chemistry 56(1): 220-240
Kim, S.D.; Cho, K.J.; Kim, J.C. 2017: Expression of cannabinoid 1 and, 2 receptors and the effects of cannabinoid 1 and, 2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats Bmc Urology 17(1): 121
Maguire, D.R.; France, C.P. 2014: Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists Journal of Pharmacology and Experimental Therapeutics 351(2): 383-389
Breivogel, C.S.; Childers, S.R. 2000: Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition Journal of Pharmacology and Experimental Therapeutics 295(1): 328-336
Maguire, D.R.; Yang, W.; France, C.P. 2013: Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration Journal of Pharmacology and Experimental Therapeutics 345(3): 354-362